cas 209412-06-6|| where to buy 2-(6-Chloro-3-pyridazinyl)-2-(2,6-dichlorophenyl)-acetonitrile

Nom du produit:2-(6-Chloro-3-pyridazinyl)-2-(2,6-dichlorophenyl)-acetonitrile

IUPAC Name:2-(6-chloropyridazin-3-yl)-2-(2,6-dichlorophenyl)acetonitrile

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM164362-5g	in stock	ȷƤƋ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 209412-06-6 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:209412-06-6; Formule moléculaire:C12H6Cl3N3; Point de fusion:-; Code SMILES:N#CC(C1=NN=C(Cl)C=C1)C2=C(Cl)C=CC=C2Cl; Densité:

: Numéro de catalogue:CM164362; Poids moléculaire:298.55; Point d'ébullition:; N° Mdl:MFCD00202119; Stockage:Store at 2-8°C.

: Pyridazines; Pyridazine, also known as o-diazobenzene, is a six-membered heterocyclic compound containing two nitrogen heteroatoms in the 1 and 2 positions with a special structure and a wide biological activity. Pyridazine is more and more popular in drug development, and a variety of pyridazine drugs have been developed and marketed. From the perspective of the therapeutic field, pyridazine drug molecules are mainly used for tumor treatment, but also involve in many therapeutic fields such as inflammation, hypertension and cardiovascular disease. With the increase and in-depth of research, pyridazine drugs will play more roles in the treatment of diseases.

: Neflamapimod; Dementia with Lewy Bodies (DLB) is a rapidly progressive neurodegenerative disorder with a significant aging population and unmet health need. Alterations in p38 mitogen-activated protein kinases (MAPKs) are found to contribute to the neurodegenerative process in Alzheimer's disease (AD) and related dementias.
CervoMed’s Neflamapimod (VX-745) is an oral, brain penetrant, small molecule inhibitor of the protein kinase p38α. It is designed to specifically target the mechanisms that cause dysfunction and degeneration of neurons in the basal forebrain cholinergic system. Neflamapimod has the potential of reversing synaptic dysfunction in the basal forebrain. The positive phase 2a data was published in Nature Communications, Neurology, and JPAD. Neflamapimod was granted Fast Track Designation by the FDA for DLB, and phase 2b enrollment was completed in June, 2024.